IB-MECA and cardioprotection

Cardiovascular Drug Reviews

Volumn 24, Issue 3-4, 2006, Pages 227-238

  Xu, Zhelong ^a   Jang, Yeongho ^a   Mueller, Robert A ^a   Norfleet, Edward A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine A3 receptor; Cardioprotection; IB MECA; Ischemia reperfusion injury

Indexed keywords

2 CHLORO 6 N CYCLOPENTYLADENOSINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR; BW A1433U; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; POTASSIUM CHANNEL; ADENOSINE; CARDIOTONIC AGENT; DRUG DERIVATIVE; N(6) (3 IODOBENZYL) 5' N METHYLCARBOXAMIDOADENOSINE; N(6)-(3-IODOBENZYL)-5'-N-METHYLCARBOXAMIDOADENOSINE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; CARDIOPLEGIA; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; ENZYME ACTIVITY; FLUSHING; HEART INFARCTION SIZE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMIC MONITORING; HUMAN; HYPERTENSION; ISCHEMIC PRECONDITIONING; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; ANIMAL; DRUG POTENTIATION; HEART INFARCTION PREVENTION;

ADENOSINE; ANIMALS; CARDIOTONIC AGENTS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL REPERFUSION INJURY; RECEPTOR, ADENOSINE A3;

EID: 33847774450     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2006.00227.x     Document Type: Review

References (79)

1. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postconditioning inhibits mitochondrial permeability transition. Circulation 2005;111:194-197.
2. 3 receptor involvement. Cardiovasc Res 1994;28:1049-1056.
3. Armstrong SC. Protein kinase activation and myocardial ischemia/reperfusion injury. Cardiovasc Res 2004;61:427-436.
4. 3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. Am J Physiol 2003;285:H607-613.
5. 2B receptor. Mol Pharmacol 1997;52:846-860.
6. 6-(3-iodobenzyl)-adenosine- 5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. Circ Res 1997;80:800-809.
7. 3 adenosine receptor ligands: History and perspectives. Med Res Rev 2000;20:103-128.
8. 3 adenosine receptor. Circ Res 2002;91:165-172.
9. Bolli R. The late phase of preconditioning. Circ Res 2000;87:972-983.
10. 3 receptors in protection of isolated human atrial muscle against simulated ischaemia. Cardiovasc Res 1997;36:52-59.
11. Chaudary N, Naydenova Z, Shuralyova I, Coe IR. The adenosine transporter, mENT1, is a target for adenosine receptor signaling and protein kinase Cε in hypoxic and pharmacological preconditioning in the mouse cardiomyocyte cell line, HL-1. J Pharmacol Exp Ther 2004;310:1190-1198.
12. ATP channel. Annu Rev Physiol 2000;62:79-109.
13. 3 adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. Am J Physiol 2002;283:H1562-1568.
14. 1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol 1998;31:1142-1149.
15. 3 receptor activation. Eur J Pharmacol 2002;441:165-172.
16. Dixon AK, Gubitz AK, Sirinathsinghji DJ, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br J Pharmacol 1990;118:1461-1468.
17. 3 receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. Br J Pharmacol 1993;109:3-5.
18. 3-selective adenosine agonists. J Med Chem 1994;37:636-646.
19. Gan XT, Rajapurohitam V, Haist JV, Chidiac P, Cook MA, Karmazyn M. Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation of multiple adenosine receptor subtypes. J Pharmacol Exp Ther 2005;312:27-34.
20. 3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. Mol Pharmacol 2001;59:76-82.
21. Gardner NM, Yates L, Broadley KJ. Effects of endogenous adenosine and adenosine receptor agonists on hypoxia-induced myocardial stunning in guinea-pig atria and papillary muscles. J Cardiovasc Pharmacol 2004;43:358-368.
22. Gateau-Roesch O, Argaud L, Ovize M. Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 2006;70:264-273.
23. Germack R, Dickenson JM. Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. J Mol Cell Cardiol 2005;39:429-442.
24. Germack R, Dickenson JM. Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes. Br J Pharmacol 2004;141:329-339.
25. Goldenberg I, Shainberg A, Jacobson KA, Shneyvays V, Grossman E. Adenosine protects against angiotensin II-induced apoptosis in rat cardiocyte cultures. Mol Cell Biochem 2003;252:133-139.
26. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-98.
27. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase B inhibition during reperfusion in intact rat hearts. Circ Res 2004;94:960-966.
28. Halestrap AP, Clarke SJ, Javadov SA. Mitochondrial permeability transition pore opening during myocardial reperfusion - a target for cardioprotection. Cardiovasc Res 2004;61:372-385.
29. Halkos ME, Kerendi F, Corvera JS, et al. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. Ann Thorac Surg 2004;78:961-969.
30. 3 receptor-mediated hypotension in the rat. Br J Pharmacol 1995;115:945-952.
31. Hausenloy DJ, Duchen MR, Yellon DM. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc Res 2003;60:617-625.
32. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol 2005;288:H971-976.
33. Hausenloy DJ, Tsang A, Yellon DM. The reperfusion injury salvage kinase pathway: A common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc Med 2005;15:69-75.
34. 3 adenosine receptor-mediated protection of the ischemic heart. Vasc Pharmacol 2005;42:271-279.
35. 3 receptors. J Pharmacol Exp Ther 1997;280:122-128.
36. 3 receptors: Novel ligands and paradoxical effects. Trends Pharmacol Sci 1998;19:184-191.
37. 3 adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. Am J Physiol 1999;277:H1895-H1905.
38. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997;280:301-309.
39. Kin H, Zatta AJ, Lofye MT, et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res 2005;67:124-133.
40. Kin H, Zhao Z-Q, Sun H-Y, et al. Postconditioning attenuates myocardial ischemia-reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004;62:74-85.
41. Klotz K-N. Adenosine receptors and their ligands. Naunyn- Schmiedeberg's Arch Pharmacol 2000;362:382-391.
42. 3 adenosine receptors. Naunyn-Schmiedeberg's Arch Pharmacol 1999;360:103-108.
43. Klotz KN, Hessling J, Hegler J, et al. Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 1998;357:1-9.
44. 1 adenosine receptor. Basic Res Cardiol 2001;96:487-496.
45. 3 receptors. Am J Physiol 2001;281:H959-968.
46. 3 receptor agonists. Biochem Biophys Res Comm 1996;219:904-910.
47. 3-receptor agonists IB-MECA and Cl-IB-MECA. Am J Physiol 1999;276:H2076-2084.
48. ATP channel. Am J Physiol 1996;271:H1769-1777.
49. 3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart. Cardiovasc Res 1994;28:1057-1061.
50. 1 adenosine receptors in rabbit heart. Circulation 1991;84:350-356.
51. 3 receptor agonist, IB-MECA. Eur J Pharmacol 2003;477:235-245.
52. 3 receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol 2002;283:H1307-1313.
53. Meyerhof W, Muller-Brechlin R, Richter D. Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. FEBS Lett 1991;284:155-160.
54. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 1986;74:1124-1136.
55. 6-(3-iodobenzyl)- adenosine-5′-N-methylcarboxamide confers cardioprotection at reperfusion by inhibiting mitochondrial permeability transition pore opening via glycogen synthase kinase 3b. J Pharmacol Exp Ther 2006;318:124-131.
56. Park SS, Zhao H, Mueller R, Xu Z. Bradykinin prevents reperfusion injury by targeting mitochondrial permeability transition pore through glycogen synthase kinase 3b. J Mol Cell Cardiol 2006;40:708-716.
57. 2b receptor cascade. Cardiovasc Res 2006;70:308-314.
58. 3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J Biol Chem 1993;268:16887-16890.
59. 3 receptors promote degranulation of rat mast cells both in vitro and in vivo. Inflamm Res 1997;46:180-184.
60. Schulte G, Fredholm BB. Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal 2003;15:813-827.
61. 3 adenosine receptor activation and its suppression by isoproterenol. Exp Cell Res 2000;257:111-126.
62. 3 adenosine receptor protects against doxorubicin-induced cardiotoxicity. J Mol Cell Cardiol 2001;33:1249-1261.
63. 3 adenosine receptor agonist. Exp Cell Res 1998;243:383-397.
64. 3 receptors during prolonged simulated ischemia. Am J Physiol 1997;273:H501-505.
65. 3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms. Circ Res 2001;88:520-528.
66. ATP channels. Am J Physiol 1999;277:H228-235.
67. 3 pretreatment before cardioplegic arrest attenuates postischemic cardiac dysfunction. Ann Thorac Surg 1999;67:1732-1737.
68. 3 receptor stimulation reduces ischemic myocardial injury in the rabbit heart. Cardiovasc Res 1997;33:410-415.
69. ATP channel activation. Cardiovasc Res 1998;40:138-145.
70. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: A form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 2004;95:230-232.
71. 3 adenosine receptor agonist, in healthy young men. Int J Clin Pharmacol Ther 2004;42:534-542.
72. 3 receptors mediates preconditioning of isolated cardiac myocytes. Eur J Pharmacol 1997;320:241-248.
73. Xu Z, Park SS, Mueller RA, Bagnell RC, Patterson C, Boysen PG. Adenosine produces nitric oxide and prevents mitochondrial oxidant damage in rat cardiomyocytes. Cardiovasc Res 2005;65:803-812.
74. Yang XM, Philipp S, Downey JM, Cohen MV. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005;100:57-63.
75. ATP channel. J Mol Cell Cardiol 2002;34:263-277.
76. 3 receptor-induced delayed cardioprotection in mouse. Am J Physiol 2003;285:H434-441.
77. Zhao Z-Q, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am J Physiol 2003;285:H579-588.
78. 2-receptor activation inhibits neutrophil-mediated injury to coronary endothelium. Am J Physiol 1996;271:H1456-H1464.
79. 3 adenosine receptor. PNAS 1992;89:7432-7436.